Fulgent Shares Are Still Very Attractive

  • Investors worry about the demise of their insanely profitable Covid business, but they shouldn’t.
  • The epic ramp in that business put the company on the map and will deliver $1B+ in cash by the end of the year.
  • They are using that bonanza wisely to accelerate their core NGS business, which is indeed accelerating.
  • Their core NGS business isn’t expensive even on a stand-alone basis at 7.5x next year’s sales, to which one can add additional Covid testing revenues.
  • Learn More »